Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

A 47-year-old man was the first in the world to be treated outside of a study context with a new technique for the symptoms ...

Learn how caffeine affects Parkinson's disease prevention and treatment. New research uncovers both protective benefits and treatment limitations.

In the past, Parkinson’s disease was primarily considered a disorder of the nervous system, centered in the brain. However, ...

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

While hand tremors are one of the most common symptoms of Parkinson’s disease it isn’t the only one There are other signs ...

A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making ... are detected in blood once symptoms have started in Lewy's body diseases, ... July 23, 2024 — Researchers ...

Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

Parkinson’s disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons ...

2024 — A small feasibility study found that an implanted device regulated by the body's brain activity could provide continual and improved treatment for the symptoms of Parkinson's disease (PD ...